BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35410253)

  • 1. Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma.
    Mo C; Wu Y; Ma J; Xie L; Huang Y; Xu Y; Peng H; Chen Z; Zeng M; Mao R
    BMC Med Genomics; 2022 Apr; 15(1):81. PubMed ID: 35410253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Significance and Potential Molecular Mechanism of Upregulated CDC28 Protein Kinase Regulatory Subunit 1B in Osteosarcoma.
    Mo C; Xie L; Chen C; Ma J; Huang Y; Wu Y; Xu Y; Peng H; Chen Z; Mao R
    J Oncol; 2021; 2021():7228584. PubMed ID: 34925510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
    Xu JH; Wang Y; Xu D
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression Profile and Molecular Basis of Cyclin-Dependent Kinases Regulatory Subunit 2 in Endometrial Carcinoma Detected by Diversified Methods.
    Gao L; Chen G; Liang ZQ; Li JD; Li DM; Tang YL; Tang D; Huang ZG; Chen JH; Luo JY; Zeng JH; Dang YW; Feng ZB
    Pathol Oncol Res; 2022; 28():1610307. PubMed ID: 35693634
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis.
    Yang Z; Cheng H; Zhang Y; Zhou Y
    Med Sci Monit; 2021 Mar; 27():e928523. PubMed ID: 33667214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
    Zhang J; Song Q; Liu J; Lu L; Xu Y; Zheng W
    Dis Markers; 2019; 2019():8964015. PubMed ID: 31781310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis.
    Zhang Y; Li Z; Huang Y; Zou B; Xu Y
    BMJ Open; 2024 Jan; 14(1):e073887. PubMed ID: 38296306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma.
    Kita Y; Nishizono Y; Okumura H; Uchikado Y; Sasaki K; Matsumoto M; Setoyama T; Tanoue K; Omoto I; Mori S; Owaki T; Ishigami S; Nakagawa H; Tanaka F; Mimori K; Mori M; Natsugoe S
    Oncol Rep; 2014 May; 31(5):1986-92. PubMed ID: 24604089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase subunit2 (CKS2) promotes malignant phenotypes and epithelial-mesenchymal transition-like process in glioma by activating TGFβ/SMAD signaling.
    Feng F; Zhao Z; Cai X; Heng X; Ma X
    Cancer Med; 2023 Mar; 12(5):5889-5907. PubMed ID: 36284444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
    Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
    Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer.
    Chen Q; Fu Y; Liu X; Wang P; Dai S; Zhu F; Liu T; Xu W; Wu J
    Mol Carcinog; 2023 Dec; 62(12):1947-1959. PubMed ID: 37642304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CKS2 modulates cell-cycle progression of tongue squamous cell carcinoma cells partly via modulating the cellular distribution of DUTPase.
    Gao F; Li C; Zhao X; Xie J; Fang G; Li Y
    J Oral Pathol Med; 2021 Feb; 50(2):175-182. PubMed ID: 33107644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma.
    Yu K; Ji Y; Liu M; Shen F; Xiong X; Gu L; Lu T; Ye Y; Feng S; He J
    Front Immunol; 2022; 13():881453. PubMed ID: 35663965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer.
    Tanaka F; Matsuzaki S; Mimori K; Kita Y; Inoue H; Mori M
    Int J Oncol; 2011 Aug; 39(2):361-72. PubMed ID: 21617860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer.
    Huang N; Wu Z; Hong H; Wang X; Yang F; Li H
    Mol Med Rep; 2019 Jun; 19(6):4761-4769. PubMed ID: 30957190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CKS2 Promotes the Growth in Non-Small-Cell Lung Cancer by Downregulating Cyclin-Dependent Kinase Inhibitor.
    Wan Z; Wang L; Yang D; Li P; Liu Q; Wang B
    Pathobiology; 2022; 89(1):13-22. PubMed ID: 34333494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/β-catenin signaling.
    Li Z; Xue TQ; Yang C; Wang YL; Zhu XL; Ni CF
    J Cell Biochem; 2018 Dec; 119(12):10327-10337. PubMed ID: 30129142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of cyclin kinase subunit 2 in human breast cancer and its prognostic significance.
    Wang J; Xu L; Liu Y; Chen J; Jiang H; Yang S; Tan H
    Int J Clin Exp Pathol; 2014; 7(12):8593-601. PubMed ID: 25674223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death.
    Lan Y; Zhang Y; Wang J; Lin C; Ittmann MM; Wang F
    Int J Cancer; 2008 Aug; 123(3):543-51. PubMed ID: 18498131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.